Xenetic Biosciences Inc   (XBIO)

Xenetic Biosciences Inc announced memorable behavior, all along the third quarter of 2022

XBIO announced third quarter of 2022 operating deficit of $-0.847786 million

Published 2022-11-12T13:40:38+00:00
Goran Soko / CSIMarket.com Contributer

Dryvax_pdIn the third quarter of 2022 the company failed to grow bottom-line, following notable Revenue elevation of 18.605 % to $0.41 million, bottom-line remained unaltered at $0.00 per share, year on year.

from the preceding quarter from $0.00 per share, Revenue decreased by -0.59 % from $0.42 million.

In the fiscal interval ending September 30 2022 Xenetic Biosciences Inc reported net loss of $-0.804 million, instead of deficit of $-1.351 million in the comparable quarter a year ago.

Xenetic Biosciences Inc is expected to report next financial results on August 10, 2023.

Xenetic Biosciences Inc's Revenue Growth

Xenetic Biosciences Inc's Dividend Growth


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071